[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100477481":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":34,"responsibleParty":52,"collaborators":20,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":20,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":20,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":78,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ctDNA collection from draining and peripheral veins","EXPERIMENTAL","Patient with suspected primary hepatobiliary or pancreatic cancer undergoing a diagnostic work-up with a percutaneous or trans-jugular biopsy (standard of care) and will undergo a sampling of the cancer draining vein during their biopsy procedure with a collection of an additional 10mL of blood.",[13],"Diagnostic Test: ctDNA Blood Collection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","ctDNA Blood Collection","Blood collection to be obtained from peripheral vein and cancer draining vein during biopsy",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Nadine Abi-Jaoudeh, MD","Chao Family Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Chao Family Comprehensive Cancer Center University of California, Irvine","CONTACT","1-877-827-7883","ucstudy@uci.edu",{"name":33,"role":29,"phone":20,"phoneExt":20,"email":20},"University of California Irvine Medical",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Chao Family Comprehensive Cancer Center, University of California, Irvine","RECRUITING","Orange","California","92868","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-117.85311,33.78779,{"lat":47,"lon":46},[50],{"name":23,"role":29,"phone":51,"phoneExt":20,"email":31},"877-827-8839",{"type":25,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Nadine Abi-Jaoudeh","Professor of Radiological Sciences","100477481","pilot-comparing-ctdna-idv-vs-spv-sample-in-pts-undergoing-biopsies-for-hepatobiliary-and-pancreatic-cancers-100477481",false,"NCT05497531","Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers","Pilot Trial Comparing Circulating Tumor DNA (ctDNA) From Immediate Draining Vein vs. Standard Peripheral Vein Sample in Patients Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers","Inclusion Criteria:\n\n* 18 years of age or older\n* Have or are undergoing work-up for hepatobiliary and\u002For pancreatic carcinoma (such as hepatocellular carcinoma, cholangiocarcinoma, ampullary carcinoma, pancreatic carcinoma)\n* Scheduled for an image-guided percutaneous or trans-jugular biopsy of a lesion\n* Must be able to provide a written informed consent\n\nExclusion Criteria:\n\n* Patients unable to hold reasonably still on a procedure table or hold their breath during imaging or needle passes\n* Patients with a gross body weight over 375 pounds (upper limit of the CT and angiography tables)\n* Patients with uncorrectable coagulopathy\n* Platelet count \\\u003C 30,000\u002Ful\n* International Normalized (INR) \\> 1.5\n* Patients with moderate to severe ascites who cannot undergo trans-jugular biopsy or sufficient drainage\n* No clear reachable target for percutaneous or trans-jugular biopsy\n* Patient who cannot have a peripheral blood draw for ctDNA","ALL","18 Years",{"count":65,"type":66},15,"ESTIMATED","INTERVENTIONAL",[69],"NA","This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies for hepatobiliary and pancreatic cancers.",[72,73,74,75,76,77],"Hepatobiliary Cancer","Pancreatic Cancer","Hepatocellular Carcinoma","Cholangiocarcinoma","Ampullary Cancer","Pancreatic Carcinoma",[79,80,73,72],"ctDNA","Circulating Tumor DNA","2026-02-23",{"date":83,"type":84},"2026-02-24","ACTUAL",{"date":86,"type":84},"2022-09-07",{"date":88,"type":66},"2026-06",{"name":5,"class":6},1]